DACS
UTHR icon

Dymon Asia Capital (Singapore)’s United Therapeutics UTHR Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Sell
1,260
-200
-14% -$113K 0.03% 182
2026
Q1 		$866K Buy
+1,460
New +$727K 0.09% 185

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Dymon Asia Capital (Singapore)'s UTHR Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) reduced its United Therapeutics (UTHR) stake by 14% in Q2 2026, selling an estimated $113K and leaving 1,260 shares worth $683K. The position accounts for 0.03% of the portfolio, ranked #182.

Dymon Asia Capital (Singapore) first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $866K in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 1,260 shares of United Therapeutics worth $683K as of Q2 2026.
  • Dymon Asia Capital (Singapore) sold 200 United Therapeutics shares in Q2 2026, an estimated $113K.
  • United Therapeutics made up 0.03% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #182 holding.
  • Dymon Asia Capital (Singapore) first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Dymon Asia Capital (Singapore)'s United Therapeutics position peaked at $866K in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.